Search Results - "McNicholl, Adrian G"

Refine Results
  1. 1

    Optimization strategies aimed to increase the efficacy of H. pylori eradication therapies by Gisbert, Javier P., McNicholl, Adrian G.

    Published in Helicobacter (Cambridge, Mass.) (01-08-2017)
    “…Background As with any other infectious disease, we should aim for treatments offering ≥90% Helicobacter pylori eradication rates in clinical practice. Aim To…”
    Get full text
    Journal Article
  2. 2

    Meta‐analysis of three‐in‐one single capsule bismuth‐containing quadruple therapy for the eradication of Helicobacter pylori by Nyssen, Olga P., McNicholl, Adrian G., Gisbert, Javier P.

    Published in Helicobacter (Cambridge, Mass.) (01-04-2019)
    “…Background Bismuth‐containing quadruple therapy has been suggested as first‐line and rescue alternative for Helicobacter pylori eradication. Our objective was…”
    Get full text
    Journal Article
  3. 3
  4. 4

    A review of rescue regimens after clarithromycin-containing triple therapy failure (for Helicobacter pylori eradication) by Marin, Alicia C, McNicholl, Adrian G, Gisbert, Javier P

    Published in Expert opinion on pharmacotherapy (01-05-2013)
    “…Helicobacter pylori infection is generally treated with therapies that include a proton pump inhibitor (PPI) and, at least, two antibiotics being…”
    Get more information
    Journal Article
  5. 5
  6. 6
  7. 7

    Protocol of the European Registry on the management of Helicobacter pylori infection (Hp‐EuReg) by McNicholl, Adrian G., O’Morain, Colm A., Megraud, Francis, Gisbert, Javier P.

    Published in Helicobacter (Cambridge, Mass.) (01-10-2019)
    “…Introduction Helicobacter pylori selectively infects the human stomach, being the most prevalent chronic infection in the world. H pylori presence causes…”
    Get full text
    Journal Article
  8. 8
  9. 9

    Sequential versus standard triple first-line therapy for Helicobacter pylori eradication by Nyssen, Olga P, McNicholl, Adrian G, Megraud, Francis, Savarino, Vincenzo, Oderda, Giuseppina, Fallone, Carlo A, Fischbach, Lori, Bazzoli, Franco, Gisbert, Javier P

    Published in Cochrane database of systematic reviews (28-06-2016)
    “…Non-bismuth quadruple sequential therapy (SEQ) comprising a first induction phase with a dual regimen of amoxicillin and a proton pump inhibitor (PPI) for five…”
    Get more information
    Journal Article
  10. 10
  11. 11
  12. 12
  13. 13

    Efficacy and Safety of Quinolone-Containing Rescue Therapies After the Failure of Non-Bismuth Quadruple Treatments for Helicobacter pylori Eradication: Systematic Review and Meta-Analysis by Marin, Alicia C., Nyssen, Olga P., McNicholl, Adrian G., Gisbert, Javier P.

    Published in Drugs (New York, N.Y.) (01-05-2017)
    “…Background Anti- Helicobacter pylori eradication treatment fails in a significant percentage of cases. Although this percentage has been reduced to 5–15% with…”
    Get full text
    Journal Article
  14. 14
  15. 15
  16. 16

    A quick flow cytometry protocol to assess Helicobacter pylori viability by Alba, Claudio, Marin, Alicia C., McNicholl, Adrian G., Montalban-Arques, Ana, Mora-Gutierrez, Irene, Sánchez-Arroyo, Antonio José, Soler, Tamara, García-Fresnadillo, David, Gisbert, Javier P., Alarcón, Teresa, Bernardo, David

    Published in Journal of microbiological methods (01-10-2020)
    “…Here we present an easy flow cytometry protocol to study the viability of Helicobacter pylori which also enables the detection of even low live bacteria…”
    Get full text
    Journal Article
  17. 17

    Spanish primary care survey on the management of Helicobacter pylori infection and dyspepsia: Information, attitudes, and decisions by McNicholl, Adrian G., Amador, Javier, Ricote, Mercedes, Cañones‐Garzón, Pedro J., Gene, Emili, Calvet, Xavier, Gisbert, Javier P.

    Published in Helicobacter (Cambridge, Mass.) (01-08-2019)
    “…Introduction Dyspepsia and Helicobacter pylori are two of the most relevant digestive conditions in primary care. Several consensuses on the subject have been…”
    Get full text
    Journal Article
  18. 18

    Questions and answers on the role of fecal lactoferrin as a biological marker in inflammatory bowel disease by Gisbert, Javier P., McNicholl, Adrian G., Gomollon, Fernando

    Published in Inflammatory bowel diseases (01-11-2009)
    “…Among the available fecal biomarkers for the diagnosis and monitoring of inflammatory bowel disease (IBD), only calprotectin and lactoferrin have translated…”
    Get full text
    Journal Article
  19. 19
  20. 20